CareDx (NASDAQ:CDNA – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare CareDx to related businesses based on the strength of its valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
Profitability
This table compares CareDx and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CareDx | 25.86% | 9.74% | 7.35% |
| CareDx Competitors | -12,516.26% | -215.91% | -31.70% |
Insider and Institutional Ownership
47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 2.4% of CareDx shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Analyst Recommendations
This is a summary of recent ratings and price targets for CareDx and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CareDx | 0 | 4 | 4 | 1 | 2.67 |
| CareDx Competitors | 9920 | 15335 | 45739 | 1601 | 2.54 |
CareDx currently has a consensus price target of $70.33, indicating a potential downside of 2.66%. As a group, “Biotechnology” companies have a potential upside of 110.28%. Given CareDx’s competitors higher possible upside, analysts plainly believe CareDx has less favorable growth aspects than its competitors.
Valuation and Earnings
This table compares CareDx and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| CareDx | $379.80 million | -$21.35 million | 30.23 |
| CareDx Competitors | $752.40 million | $11.26 million | -18.35 |
CareDx’s competitors have higher revenue and earnings than CareDx. CareDx is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
CareDx beats its competitors on 7 of the 13 factors compared.
About CareDx
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
